Louisa Degenhardt1, Nicholas Lintzeris2, Gabrielle Campbell3, Raimondo Bruno4, Milton Cohen5, Michael Farrell3, Wayne D Hall6. 1. National Drug and Alcohol Research Centre, UNSW, Australia; School of Population and Global Health, University of Melbourne, Australia. Electronic address: l.degenhardt@unsw.edu.au. 2. Discipline of Addiction Medicine, University of Sydney, Australia; The Langton Centre, South East Sydney Local Health District (SESLHD) Drug and Alcohol Services, Australia. 3. National Drug and Alcohol Research Centre, UNSW, Australia. 4. National Drug and Alcohol Research Centre, UNSW, Australia; School of Medicine, University of Tasmania, Australia. 5. St Vincent's Clinical School, UNSW Medicine, UNSW, Australia. 6. Centre for Youth Substance Abuse Research, University of Queensland, Australia; National Addiction Centre, Kings College, London, England, United Kingdom.
Abstract
BACKGROUND: There is increasing debate about cannabis use for medical purposes, including for symptomatic treatment of chronic pain. We investigated patterns and correlates of cannabis use in a large community sample of people who had been prescribed opioids for chronic non-cancer pain. METHODS: The POINT study included 1514 people in Australia who had been prescribed pharmaceutical opioids for chronic non-cancer pain. Data on cannabis use, ICD-10 cannabis use disorder and cannabis use for pain were collected. We explored associations between demographic, pain and other patient characteristics and cannabis use for pain. RESULTS: One in six (16%) had used cannabis for pain relief, 6% in the previous month. A quarter reported that they would use it for pain relief if they had access. Those using cannabis for pain on average were younger, reported greater pain severity, greater interference from and poorer coping with pain, and more days out of role in the past year. They had been prescribed opioids for longer, were on higher opioid doses, and were more likely to be non-adherent with their opioid use. Those using cannabis for pain had higher pain interference after controlling for reported pain severity. Almost half (43%) of the sample had ever used cannabis for recreational purposes, and 12% of the entire cohort met criteria for an ICD-10 cannabis use disorder. CONCLUSIONS: Cannabis use for pain relief purposes appears common among people living with chronic non-cancer pain, and users report greater pain relief in combination with opioids than when opioids are used alone.
BACKGROUND: There is increasing debate about cannabis use for medical purposes, including for symptomatic treatment of chronic pain. We investigated patterns and correlates of cannabis use in a large community sample of people who had been prescribed opioids for chronic non-cancer pain. METHODS: The POINT study included 1514 people in Australia who had been prescribed pharmaceutical opioids for chronic non-cancer pain. Data on cannabis use, ICD-10 cannabis use disorder and cannabis use for pain were collected. We explored associations between demographic, pain and other patient characteristics and cannabis use for pain. RESULTS: One in six (16%) had used cannabis for pain relief, 6% in the previous month. A quarter reported that they would use it for pain relief if they had access. Those using cannabis for pain on average were younger, reported greater pain severity, greater interference from and poorer coping with pain, and more days out of role in the past year. They had been prescribed opioids for longer, were on higher opioid doses, and were more likely to be non-adherent with their opioid use. Those using cannabis for pain had higher pain interference after controlling for reported pain severity. Almost half (43%) of the sample had ever used cannabis for recreational purposes, and 12% of the entire cohort met criteria for an ICD-10 cannabis use disorder. CONCLUSIONS: Cannabis use for pain relief purposes appears common among people living with chronic non-cancer pain, and users report greater pain relief in combination with opioids than when opioids are used alone.
Authors: Jenny L Wilkerson; Sudeshna Ghosh; Mohammed Mustafa; Rehab A Abdullah; Micah J Niphakis; Roberto Cabrera; Rafael L Maldonado; Benjamin F Cravatt; Aron H Lichtman Journal: Neuropharmacology Date: 2016-11-25 Impact factor: 5.250
Authors: Joanna L Starrels; Sarah R Young; Soraya S Azari; William C Becker; E Jennifer Edelman; Jane M Liebschutz; Jamie Pomeranz; Payel Roy; Shalini Saini; Jessica S Merlin Journal: Pain Med Date: 2020-02-01 Impact factor: 3.750
Authors: Alex H Kral; Lynn Wenger; Scott P Novak; Daniel Chu; Karen F Corsi; Diana Coffa; Brad Shapiro; Ricky N Bluthenthal Journal: Drug Alcohol Depend Date: 2015-05-22 Impact factor: 4.492